Thrombin Generation and Thromboelastography in Non-overt DIC
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Sepsis is the 13th most common cause of death in the United States, causing approximately 210,000 deaths per year. Once DIC has developed, irreversible organ injury has already occurred and the mortality rate is 70%. Inhibition of systemic coagulation with activated protein C concentrate has been the only therapy for sepsis introduced in the past several decades which has improved outcomes. Elucidation of the coagulopathic mechanisms early in the development of DIC may give rise to targeted therapies and strategies for early intervention. We hypothesize that an increase in endogenous thrombin potential precedes the development of overt DIC by a clinically significant time period. Our primary objective is to determine if endogenous thrombin potential (ETP) measured at first diagnosis of sepsis prior to the onset of DIC and organ failure is predictive of overt DIC and/or poor outcome. We will compare ETP to standard coagulation assays and the clinical assessment of DIC using the ISTH criteria for overt DIC. A secondary objective of this study is to determine if host coagulation variables predispose to the development of DIC and poor clinical outcome during sepsis.
| Condition |
|---|
|
Sepsis Disseminated Intravascular Coagulation |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Use of Whole Blood and Cell-rich Coagulation Assays for the Detection of Non-Overt DIC in Sepsis |
- Mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]ETP will be used to predict 28 day mortality
Biospecimen Retention: Samples Without DNA
Samples will be discarded after the study is completed.
| Enrollment: | 2 |
| Study Start Date: | October 2006 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients arriving in Emergency Department with sepsis (systemic inflammatory response syndrome).
Inclusion Criteria:
- Systemic inflammatory response syndrome with known or suspected infection
- Patient to be admitted to the hospital
Exclusion Criteria:
- Diabetic ketoacidosis, Hemophilia, weight < 25 kg, use of hemostatic agents prior to entry.
Contacts and Locations| United States, Texas | |
| Memorial Hermann Hospital | |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Deborah L. Brown, M.D. | The University of Texas Health Science Center, Houston |
More Information
No publications provided
| Responsible Party: | Deborah Brown, Associate Professor, Pediatrics, The University of Texas Health Science Center, Houston |
| ClinicalTrials.gov Identifier: | NCT00299949 History of Changes |
| Other Study ID Numbers: | HSC-MS-06-0012 |
| Study First Received: | March 3, 2006 |
| Last Updated: | February 6, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Disseminated Intravascular Coagulation Sepsis Toxemia Blood Coagulation Disorders Hematologic Diseases Hemorrhagic Disorders |
Thrombophilia Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 16, 2013